Improved nerve visualization to reduce unintended intraoperative nerve injury

Developing a clinical solution to enhance real-time intraoperative visualization of nerves for surgeons

Illuminare Biotechnologies

Illuminare Biotechnologies is a clinical stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage. Our proprietary lead candidate, Illuminare-1, is a small molecule with an immediate onset of action and sustained duration of nerve illumination. Illuminare-1 has completed a first-in-human trial in radical prostatectomy at Memorial Sloan Kettering Cancer Center and demonstrated safety and initial efficacy, improving visualization of nerves. Results of the Phase 1 trial were published on July 2025 in world-renowned JAMA Surgery. The article was accompanied by an invited editorial commentary. The company expects to enter Phase 2 in 2026.

Learn More
Image